no weight loss first week of semaglutide Adults receiving semaglutide as their

Different GLP-1 receptor agonists have varying pharmacokinetic profiles and receptor binding characteristics

Dysaesthesia has been reported in some clinical trials of semaglutide, including the STEP UP T2D trial of subcutaneous semaglutide, results of which showed that the adverse effect was more common with 7.2 mg doses (n=58 [18.9%] of 307) compared with 2.4 mg doses (n=five [4.9%] of 103)

Another important topic is the use of semaglutide during breast cancer treatment

But treatment is not always standard

In our cohort, the majority of patients exhibited active IIH, especially in the UCWM group with significantly shorter disease duration, with slightly higher yet not significant change in the pRNFL thickness in this group